Search the Newsreel

Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors

Corbus Pharmaceuticals Holdings Inc. (CRBP) stock dropped 3.91% on Tuesday, closing at $10.08. This underperformance occurred during a general market downturn, with both the NASDAQ Composite Index and Dow Jones Industrial Average also experiencing losses. The decline ended a five-day winning streak for the …

Arrowhead (NASDAQ: ARWR) director to sell 2,000 shares

A director at Arrowhead Pharmaceuticals Inc. (ARWR), Adeoye Olukotun, has filed a Rule 144 notice to sell 2,000 shares of common stock through Merrill Lynch. The proposed sale, valued at $173,876.47, is expected around August 18, 2026, on NASDAQ. These shares were originally acquired …

Mirum Pharma (NASDAQ: MIRM) officer lines up $4M share sale

Jolanda Marie Howe, an officer at Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), has filed a Form 144 to sell 40,000 common shares valued at $4,000,000.00 on August 18, 2026, following a stock option exercise. The sale will be executed through Morgan Stanley Smith Barney. The …

Processa Pharmaceuticals (NASDAQ: PCSA) gains new 5.8% owner with no sole control

Soleus Capital Master Fund, L.P. and related entities, including Guy Levy, have reported a beneficial ownership of 160,943 shares of Processa Pharmaceuticals (PCSA), representing 5.8% of the outstanding common stock. This ownership grants shared voting and dispositive power but no sole control. The filing …

Rhythm (RYTM) CMO reports no company stock holdings

Rhythm Pharmaceuticals, Inc. (RYTM) Chief Medical Officer, Joshi Manher, has filed an initial statement of beneficial ownership (Form 3) indicating no equity transactions or holdings in the company. The filing includes an Exhibit 24 for a Power of Attorney, allowing filings to be made …

Rhythm Pharmaceuticals (RYTM) grants CMO 50K options expiring 2036

Rhythm Pharmaceuticals (RYTM) has granted its Chief Medical Officer, Manher Joshi, 50,000 stock options with an exercise price of $115.44, expiring in 2036, and 25,000 Restricted Stock Units (RSUs). The stock options vest over four years, while the RSUs vest annually from 2027 to …

Recursion Pharmaceuticals Inc (RXRX) News, Articles, Events & Latest Updates

MIRA (MIRA) Financial Results: The Company Lists Its Latest Available Figures in the Latest Session; Investor Response: Shares Fall 3.16% in the Latest Reading - Segment Revenue Breakdown

BioMarin looks to spur growth with potential $490M buyout of Dutch bone drug company

BioMarin Pharmaceutical is reportedly looking to acquire Dutch bone drug company Alesa Therapeutics for up to $490 million, including a $275 million upfront payment. This potential acquisition comes shortly after BioMarin decided to halt the late-stage development of another drug. The move is seen …

Verrica (NASDAQ: VRCA) CEO buys 25,000 shares in August

Verrica Pharmaceuticals Inc. (VRCA) CEO Jayson Rieger purchased 25,000 shares of common stock in August 2026. These open-market transactions included 5,000 shares bought on August 17 at $4.91 per share and 20,000 shares on August 14 at a weighted average price of $5.06. The …

Verrica (NASDAQ: VRCA) interim CFO adds 5,000 shares in open-market buy

Verrica Pharmaceuticals Inc.'s Interim CFO, John J. Kirby, purchased 5,000 shares of common stock in the open market on August 18, 2026. The shares were bought at a weighted average price of $4.93, with individual trades ranging from $4.85 to $4.99 per share. Following …

LUCIDITY Shows Clear Phase III Win For Amylyx’s Avexitide

Amylyx's Avexitide achieved a clear Phase III win in the LUCIDITY trial for patients with post-bariatric hypoglycemia (PBH). The company plans to submit the drug to the US FDA by the end of 2026. This positive outcome follows a previous late-stage drug failure for …

Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses

International Business Machines Corp. stock outperforms competitors on strong trading day

International Business Machines Corp. (IBM) shares rose 1.67% to $232.67 on Tuesday, outperforming the broader market which saw the S&P 500 Index fall 0.69% and the Dow Jones Industrial Average fall 0.22%. This gain broke a two-day losing streak for the stock.

These 2 Stocks Are Setting Off Technical Alarm Bells with $1,000+ Price Tags. Here’s the Company I’d Bet on for the Long Term.

Buy Sell cards by Kelly Sikkema via Unsplash Virginia-based conglomerate Graham Holdings (GHC)was one of Barchart's 200 bearish price surprises in Monday trading. It was down 2.2% on the day to $1,165.29; its standard deviation was -1.67, far from the highest, Eyepoint (EYPT), at …

MacroGenics (MGNX) exec adds 40K shares via option exercise

MacroGenics (MGNX) Senior VP, Research & CSO Ezio Bonvini, reported exercising 40,000 employee stock options at $2.60 per share on August 17, 2026, and holding the acquired common stock. Following this transaction, Bonvini directly holds 185,799 shares of common stock and 88,000 employee stock …

Rocket Pharma (NASDAQ: RCKT) sale tied to 2026 vesting, tax bill

Gaurav Shah, associated with Rocket Pharmaceuticals (RCKT), has filed a Rule 144 notice to sell 2,293 shares of restricted common stock. This proposed sale is linked to restricted stock vesting on August 14, 2026, and partially aims to cover a tax obligation from a …

Rocket Pharma (NASDAQ: RCKT) ex-officer to unload equity-award shares

A former officer of Rocket Pharmaceuticals (NASDAQ: RCKT), John Militello, has filed a Form 144 notice to sell 1,252 shares of common stock. The filing, dated August 18, 2026, details two recent restricted stock vesting events in August 2026 and a sale of 384 …

Basilea Pharmaceutica AG erhöht Gewinnprognose für das Gesamtjahr 2026

SPRY Shareholder Alert: ARS Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), announcing a securities class action lawsuit. This alert is for investors who purchased SPRY shares between March 9, 2026, and June 24, 2026, due to alleged misleading statements regarding …

Amylyx Pharmaceuticals Inc. (AMLX) Stock Price | Live Quotes & Charts | NASDAQ

Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts (AMLX)

Amylyx Pharmaceuticals (AMLX) has been upgraded to "Strong Buy" following positive Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia (PBH), which met its primary endpoint with a 55% reduction in severe hypoglycemic events and a favorable safety profile. Key upcoming catalysts include …

Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues

Xeris Biopharma Holdings (XERS) is gaining attention after tighter full-year revenue guidance and second-quarter results were released on August 6, 2026. The stock is considered 22.8% undervalued with a fair value of $11.14 per share, compared to its current price of $8.60. This valuation …

Takeda Pharmaceutical (TSE:4502) Wins FDA Approval For ORZEYFUL, Is The Stock Still Cheap?

Takeda Pharmaceutical's stock is in focus after its ORZEYFUL drug received FDA approval for narcolepsy type 1, leading to positive share price returns. The company is considered 9% undervalued with a fair value of ¥6,262.69, driven by anticipated earnings recovery post-VYVANSE generic erosion and …

ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year High - Here's What Happened

ACADIA Pharmaceuticals (NASDAQ:ACAD) recently hit a new 52-week high of $29.87, closing near $29.62, driven by positive analyst sentiment and strong financial results. The company's recent earnings exceeded expectations, reporting $0.18 EPS against an anticipated $0.07, and revenue grew 16.4% year-over-year to $308 million. …

Ramaco (METC) Earnings Recap: Profit Per Share Clears Its Benchmark on the Day; Investor Response

Ligand (LGND) Latest Results Brief: EPS Exceeds Its Estimate on the Day; Price Action: The Stock Ends Down 1.27% in Latest Trading - Earnings Call Highlights

Basilea Pharmaceutica Aktie (BSLN) | Aktienkurs » CH0011432447

Eloxx Pharmaceuticals, Inc. Statistics – FWB:J36

This page provides an overview of financial statistics for Eloxx Pharmaceuticals, Inc. (J36 on the Frankfurt Stock Exchange). It outlines various key financial metrics, valuation ratios, profitability ratios, liquidity ratios, solvency ratios, and per-share metrics. However, all listed data fields for annual and quarterly …

Ionis (IONS) Financial Update: The Bottom-Line Figure Beats Its Comparison; Closing Response: Shares Finish 1.71% Up - Energy Earnings Report

Traders Buy Large Volume of Call Options on Eyepoint Pharmaceuticals (NASDAQ:EYPT)

EYPT Stock Crashes On Duravyu Data But Catalysts Loom

EyePoint Pharmaceuticals (EYPT) stock initially crashed by 69% after its Phase 3 LUGANO trial for DURAVYU in wet AMD missed its primary vision endpoint on the full dataset. However, an ad hoc analysis, excluding an asymmetric cohort, showed non-inferiority against aflibercept and other strong …

Citigroup Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price

Citigroup has significantly cut its price target for Eyepoint Pharmaceuticals (NASDAQ:EYPT) from $35.00 to $17.00, while still maintaining a "buy" rating, indicating a potential upside of 216.10% from its current price of $5.38. This downgrade follows the failure of the company's LUGANO trial for …

MACOM, Seagate, and Entegris Stocks Trade Down, What You Need To Know

MACOM, Seagate, and Entegris Stocks Trade Down, What You Need To Know What Happened? A number of stocks fell in the morning session after the 30-year U.S. Treasury yield hit a 19-year high and oil stayed elevated as a window for a U.S.–Iran deal …

ETFs Investing in Eloxx Pharmaceuticals, Inc. Stocks

This article lists ETFs that invest in Eloxx Pharmaceuticals, Inc. stocks, providing details such as market value, weight, issuer, and management style for each fund. It aims to help investors find opportunities with lower risk by investing in these ETFs. The primary ETF mentioned …

ORCL Stock: Why The Discount May Not Last

Image by Pexels from Pixabay The company's backlog has quietly swelled to a record size. Remaining performance obligations finished at $638 billion, a figure that redefines its growth trajectory. This massive book of business, up 363%, was bolstered by signing $67 billion in AI …